A clinical-stage biotechnology company developing antibody-based cancer therapies designed to activate primarily within the tumor microenvironment. Its Probody platform aims to improve the safety and efficacy of targeted biologics by masking therapeutic activity until the drug reaches tumor tissue. ...
1 member of Congress has disclosed 1 trade in CytomX Therapeutics, Inc. (CTMX), a Healthcare company. The buy/sell breakdown shows 1 purchase versus 0 sales, indicating net buying interest from lawmakers. All data is sourced from STOCK Act periodic transaction reports filed with Congress.
| Date | Politician | Type | Amount |
|---|---|---|---|
| 2025-04-10 | Kelly Louise Morrison | buy | $1K – $15K |